- Why Research
- Our Impact
- Get Involved
- About BCRF
- Research is the reason
- Contact Us
- The Hot Pink Party
You are here
Jean Zhao, PhD
Professor, Biological Chemistry & Molecular Pharmacology
Harvard Medical School
Professor, Cancer Biology, Dana-Farber Cancer Institute
Co-leader, Breast Cancer Program, Dana-Farber/Harvard Cancer Center
Goal: To identify new strategies for the treatment of metastatic breast cancer (MBC), particularly breast cancers that have spread to the brain.
Impact: Dr. Zhao has been studying how breast tumors evade attack by the immune system and evaluating treatments against breast cancer brain metastases. Her work has the potential to significantly reduce the burden of advanced breast cancer, particularly brain metastases, and to improve the lives of patients and their loved ones affected by this disease.
What’s next: She and her team will continue to use sophisticated models of breast cancer metastasis to develop effective therapeutic strategies against specific subtypes of breast cancer and brain metastases.
MBC is breast cancer that has spread beyond the breast and nearby lymph nodes to other organs in the body. The brain is a common site of breast cancer metastasis. Breast cancers that have spread to the brain present a unique clinical challenge for doctors, making new treatments a clinical priority. Dr. Zhao is conducting studies on the effectiveness of combinations of targeted and immunotherapies directed against specific molecular abnormalities typically found in advanced and MBC.
Full Research Summary
Research area: Developing safe and effective combinations of targeted and immunotherapies directed at specific molecular abnormalities typically found in advanced and metastatic breast cancer (MBC).
Impact: Patients who have advanced breast cancer—particularly those with brain metastases—frequently face a poor prognosis. Effective therapies are limited and often have toxic side effects. Dr. Zhao is conducting laboratory tests of new, highly promising drugs and immunotherapy combinations that target vulnerabilities of MBC cells. Her work will likely have profound implications in advancing treatment options for patients with MBC.
Current investigation: Dr. Zhao and her colleagues have been deciphering important mechanisms by which breast tumors evade attack by the immune system. In addition, they’re conducting preclinical studies on the effectiveness of treatments against breast cancer brain metastases.
What’s next: The team will build upon their success in developing therapeutic strategies against specific subtypes of breast cancer and brain metastases by incorporating new targets that could:
- Help prevent the development of resistance to therapy;
- Increase the effectiveness of immunotherapy strategies to significantly enhance long-term survival;
- Effectively treat breast cancer that have spread to the brain
Jean Zhao is Professor of Biological Chemistry and Molecular Pharmacology at Harvard Medical School and Dana-Farber Cancer Institute (DFCI). Dr. Zhao’s research centers on understanding kinase signaling pathways in cancer. She has pioneered a new front in understanding signal transduction by integrating genetics and pharmacological approaches, thus changing the way we think about important problems in the targeted therapy of cancer. Specifically, she has conducted seminal work to determine distinct roles of isoforms of PI3K in the normal physiological functions and in the pathogenesis of cancer. Her work laid a foundation for the new field of targeting isoforms of PI3K in cancer and guided the design of current clinical trials of PI3K inhibitors for cancer patients. Dr. Zhao is a leader in the systems and functional approaches to targeting kinases in cancer, and has identified a number of novel oncogenic kinases and lead compounds, providing the groundwork for innovative therapeutic interventions. More recently, she is leading a major effort to establish patient-derived models of metastatic breast cancer. This work is designed to investigate the molecular and genetic basis for this disease and the mechanisms of drug resistance in order to translate fundamental preclinical findings into novel and improved therapeutic strategies for patients. Dr. Zhao’s honors and awards include Career Development Awards from NIH/NCI, V Scholar Award and Starr Foundation Award. She is a member of Committee for Women Faculty and Executive Committee for Research at DFCI, and serves as Co-Leader of the Breast Cancer Program at Dana-Farber/Harvard Cancer Center.